New perspectives in the treatment of rheumatoid arthritis;Nuevas perspectivas en el tratamiento de la artritis reumatoide

Farmacia Hospitalaria

Volumn 27, Issue 6, 2003, Pages 360-370

  Martín Alcalde, Eva ^a   Cantero Blanco, S ^a   Sanchez Garcia F J ^a   Gomez Castillo J J ^a  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Adalimumab; Anakinra; Etanercept; Infliximab; Interleukin 1; Rheumatoid arthritis; Tumoral necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; DRUG EFFICACY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HUMAN; PHYSICAL DISABILITY; POPULATION RESEARCH; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SPAIN;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS;

EID: 0346500883     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. American College of Rheumatology Subcommittee on Rheumatoid Artritis Guidelines. Guidelines for the Management of Rheumatoid Arthritis. Arthritis Rheum 2002; 46: 328-46.
2. Treatment Options for patients with severe Rheumatoid Arthritis are gradually increasing. Drug & Ther Perspect 2001; 17 (12): 4-8.
3. Diario Médico. Noviembre 2000.http://www.diariomedico.com/reumatología.
4. Rosenberg H. Enfermedades del mesénquima. http://escuela.med.puc.c1/paginas/publicaciones/AnatomiaPatologica/11Eng..../ 11artritis.htm. Consultada el 08/10/2002.
5. Diario médico. Septiembre 2002. http://www.diariomé dico.Com/edicion/componentes/noticia
6. Diario medico. Julio 2002. http://www.diario mé dico.Com/edicion/componentes/noticia.
7. La Artritis Reumatoide. El sinuoso y común mal de nuestros abuelos. http://www.artritisreumatoide/artrireumapatoge.htm. Consultada el 08/10/02.
8. Rheumatoid arthritis: Decreasing Joint Damage and Pain. 〈httm: arthritis reumatoide /Rheumatoid Arthritis Decreasing Joint Damage and Pain. htm〉.
9. a ed. España: Prensa médica Mexicana; 1979: 2447-52.
10. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43 (12): 2619-33.
11. Arend WP, Dayer J-M. Inhibition of the production and effects of IL-1 and TNF in Rheumatoid Arthritis. Arthritis Rheum 1995; 38: 151-60.
12. Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha (TNFα) inhibitors. Med Clin 2001; 116: 620-8.
13. Arnett FC, Edworthy SM, Bioch DA, et al. The American Rheumatism Associations 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
14. Comité de expertos de la SER. Actualización del consenso de la Sociedad Española de Reumatología sobre la terapia con agentes inhibidores del TNF en la artritis reumatoide. Rev Esp Reum 2002; 29 (2): 51-5.
15. Wolfe F, Cush JJ, O'Dell JR, Kavanaugh A, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001; 28: 1423-30.
16. Fármacos para la Artritis Reumatoide. The Medical Letter, edición española 2000; XXII: 75-81.
17. Leonard H Calabrese. Anakinra treatment of patients with Rheumatoid Arthritis. The Annals of Pharmacotherapy 2002 Jul/Aug; 36: 1204-9.
18. Dayer Jean-Michel, Bresnihan Barry. Targeting Interleukin-1 in the treatment of rheumaoid Arthitis. Arthritis & Rheumatism 2002; 46 (3): 574-8.
19. Ficha técnica e informe de evaluación científica de Infliximab de la EMEA. http://www.eudra.org.
20. The role of biologics optimizing RA treatment. 〈 htpp://www.medscape.com/viewprogram/1320-pnt.〉
21. Ficha técnica e informe de evaluación científica de Etanercept de la EMEA. http://www.eudra.org.
22. Ficha técnica e informe de evaluación científica de Anakinra de la EMEA. http://www.eudra.org.
23. Anakinra. Micromedex 2002
24. Amy K. Erikson. Interleukin-1 blocker for rheumatoid arthritis. Pharmacy Today 2002; 8 (4): 4.
25. Anakinra http://home.mdconsult.com/das/drug/body/98705410/1/3534.html. Consultado 18/04/02.
26. Small RE, Wisted MA, Neal Roberts W. Anakinra. An interleukin-1 receptor antagonist for treatment of rheumatoid arthritis. Formulary 2001; 36: 191-203.
27. Cohen, et al. Tratamiento de la artritis reumatiode con anakinra, un antagonista del receptor de la IL-1 recombinante humano, en combinación con metotrexato. Arthritis & Rheumatism 2002; 46 (3): 614-24.
28. Bresnihan B, Álvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Tratment or Rheumatoid Arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis & Rheumatism 1998; 41 (12): 2196-204.
29. Jiang Y, Genant H, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis & Rheumatism 2000; 43 (5): 1001-9.
30. Bresnihan Barry. Perspectivas de tratamiento de la artritis reumatiode con antagonista del receptor de interleucina-1 humano recombinante.
31. Anti-TNF-alpha Therapy Today and Tomorrow. 〈D:artritisreumatoide The New Science of Rheumatoid Arthritis Treatment.htm〉.